LONG‐ACTING INHALED β2‐AGONISTS IN THE MANAGEMENT OF ASTHMA: RECENT ADVANCES AND CURRENT RECOMMENDATIONS

Abstract

SUMMARY Salmeterol and formoterol belong to a new class of inhaled β2‐agonists with a prolonged duration of action. At the time these agents were introduced, there was uncertainty regarding the safety of β2‐agonist therapy in asthma and concern that they might lead to a deterioration in asthma control. Recent studies, in contrast, have demonstrated both their safety and therapeutic efficacy. The aims of this review are to highlight these new developments and to consider the place of these long‐acting β2‐agonists in asthma management strategies.